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Abstract
Introduction: The present study examined the median survival, life expectancies, and cumulative incidence rate
(CIR) of patients undergoing prolonged mechanical ventilation (PMV) stratified by different underlying diseases.
Methods: According to the National Health Insurance Research Database of Taiwan, there were 8,906,406
individuals who obtained respiratory care during the period from 1997 to 2007. A random sample of this
population was performed, and subjects who had continuously undergone mechanical ventilation for longer than
21 days were enrolled in the current study. Annual incidence rates and the CIR were calculated. After stratifying
the patients according to their specific diagnoses, latent class analysis was performed to categorise PMV patients
with multiple co-morbidities into several groups. The life expectancies of different groups were estimated using a
semiparametric method with a hazard function based on the vital statistics of Taiwan.
Results: The analysis of 50,481 PMV patients revealed that incidence rates increased as patients grew older and
that the CIR (17 to 85 years old) increased from 0.103 in 1998 to 0.183 in 2004 before stabilising thereafter. The life
expectancies of PMV patients suffering from degenerative neurological diseases, stroke, or injuries tended to be
longer than those with chronic renal failure or cancer. Patients with chronic obstructive pulmonary disease survived
longer than did those co-morbid with other underlying diseases, especially septicaemia/shock.
Conclusions: PMV provides a direct means to treat respiratory tract diseases and to sustain respiration in
individuals suffering from degenerative neurological diseases, and individuals with either of these types of
conditions respond better to PMV than do those with other co-morbidities. Future research is required to
determine the cost-effectiveness of this treatment paradigm.
Introduction
The number of patients who require prolonged mechan-
ical ventilation (PMV) is rapidly increasing worldwide,
apparently due to aging, a greater number of co-morbid-
ities, and the increasing availability and effectiveness of
this new technology [1-3]. The fact that many patients
require continued respiratory care after being trans-
ferred into a rehabilitation facility creates a tremendous
financial burden [3,4]. Furthermore, there is often a gap
between families’ unreasonably optimistic expectations
and clinicians’ professional judgement. This gap fre-
quently results in difficulties arriving at consensus clini-
cal decision-making [5]. In many cases, these challenges
are not easily resolved. These issues are exacerbated by
the lack of evidence regarding expected survival times
for different subgroups of patients, especially for those
suffering from multiple co-morbidities.
The National Health Insurance (NHI) of Taiwan has
implemented a system of comprehensive coverage for
various healthcare services, including maintenance
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was first established in 1995 and has been extended to
cover over 99% of the citizens of Taiwan [6,7]. In 1998,
the Bureau of the NHI drafted a prospective payment
programme to encourage integrated care for mechani-
cally ventilated patients, which was implemented in July
2000 [8]. After several revisions, this programme ulti-
mately covered mechanical ventilator care in the follow-
ing settings: ICUs (acute stage, <21 days), respiratory
care centres (a subacute stage for weaning training, up
to 42 days), respiratory care wards (a chronic stage or
long-term care), and homecare services (a stable stage
during which the patient is cared for directly by family
caregivers). The rising number of patient-days for
mechanical ventilation usage during 1997 to 2004
increased the financial burden of the NHI [9].
Similar to the case in western countries [5], discrepan-
cies frequently exist in Taiwan between a family’si n i t i a l
expectations and their physician’sp r o f e s s i o n a lj u d g e -
ment. These discrepancies impair communication
among patients, their families, and healthcare workers
for clinical decision-making before and throughout the
course of installing mechanical ventilation. There is thus
a need to estimate the incidence rates and life expectan-
cies for PMV patients with various diagnoses. Accurate
prognoses are essential to propose and establish a sus-
tainable national policy and to facilitate communication
among different stakeholders. To examine the above
issues, we collected a random sample from the national
database and compared age-specific incidence rates,
cumulative incidence rates (CIRs), median survival, and
life expectancies of PMV patients stratified according to
their underlying diseases.
Materials and methods
Study population, datasets, and calculation of age-
specific and cumulative incidence rates
The present study was approved by the Institutional
Review Board of the National Taiwan University Hospi-
tal, which also waived the requirement for obtaining
informed consent because the study was conducted on a
secondary database with encrypted identification num-
bers. The reimbursement data file obtained from the
NHI of Taiwan was transformed into a research data-
base by the National Health Research Institutes (in Chu-
nan, Taiwan) [10]. The identification numbers of all
individuals in the reimbursement data file were
encrypted to protect their privacy. These files contained
detailed demographic data (including birth date and sex)
and information regarding the healthcare services pro-
vided for each patient, including all payments for outpa-
tient visits, hospitalisations, prescriptions, diagnoses, and
intervention procedures. The data for each inpatient
hospitalisation included up to five diagnoses, which
were coded according to the International Classification
of Diseases (Ninth Revision) and the date of each pre-
scription or procedure. In total, 8,906,406 individuals
had undergone invasive or non-invasive respiratory care
at least once during the period from 1997 to 2007. This
number corresponds to approximately 29.4% of the
entire insured population. Because the government has
established guidelines stating that no more than 10% of
all data can be drawn for research, we applied for a ran-
dom sample of these patients with a 3.4:1 ratio and
enrolled subjects who had undergone mechanical venti-
lation for longer than 21 days.
According to the definition of PMV in Taiwan [8], we
included patients over the age of 17 who had undergone
either invasive or non-invasive mechanical ventilation,
with negative or positive pressure ventilators for at least
21 consecutive days in the ICU or the respiratory care
centre. To ensure that all of the patients were incident
cases, we excluded all prevalent cases found in 1997 and
began the collection in 1998, as illustrated in Figure 1.
The calendar year-specific and age-specific incidence
rates were determined by taking the number of new
cases of PMV patients in that stratum, multiplying by
the sampling factor of 3.4, and then dividing the result-
ing value by the number of individuals within the speci-
fic stratum obtained from the census of the Ministry of
t h eI n t e r i o ri nT a i w a n[ 1 1 ] .T h eC I R( c u m u l a t i v ei n c i -
dence rate) formula was calculated as follows [12]:
CIR = 1 − exp[− i (IRi)( ti)]
where IRi represents the age-specific incidence rate
and Δti indicates the range of each age stratum. We cal-
culated the CIR17 to 85, which estimates the likelihood
that an average person in Taiwan would require PMV
assuming that he or she lives to the age of 85.
Categorisation of patients for estimation of life
expectancies
All recruited subjects were followed until the end of
2007 to determine whether they were alive, deceased, or
censored. Because patients who had undergone PMV
usually suffered from a combination of multiple co-
morbidities and five major diagnoses can be retrieved
for each PMV patient prior to and closest to the first
day, we developed a strategy to identify different homo-
geneous groups to make more accurate estimates of life
expectancy.
First, we excluded specific categories with extremely
low frequencies, including HIV infection (n = 27) and
complications during pregnancy/childbirth/perinatal per-
iod (n = 240). Second, people with major diagnoses that
may cause premature mortality were stratified and ana-
lysed separately, including cancer, end-stage renal
Hung et al. Critical Care 2011, 15:R107
http://ccforum.com/content/15/2/R107
Page 2 of 9disease, liver cirrhosis, multiple sclerosis or degenerative
neurological diseases, Parkinson’s disease, and injury or
poisoning, as each group shares major common charac-
teristics that predict mortality. Third, because the vast
majority of patients suffered from a combination of
multiple chronic diseases that may cause premature
mortality, such as diabetes mellitus, coronary and/or
heart failure, hypertension, respiratory system and/or
urinary tract infections, acute renal failure, septicaemia
with and without shock, and so forth, we conducted
latent class analysis (LCA) for these cases to categorise
them into clusters or specific homogeneous groups for
Patients with one or more order codes 
of respiratory care between 1997-2007 
(n=8,906,406)
Simple random sampling with a fixed 
ratio of 3.4:1 from the above patients 
(n=2,619,534)
New cases of prolonged mechanical 
ventilation after 1998 (n=50,481) 
Inclusion criteria: 
(1) Adults who were more 
than 17 years old 
(2) Who had also 
undergone mechanical 
ventilation for more than 
21 days, using an invasive 
ventilator, a negative 
pressure ventilator, 
noninvasive or a positive 
pressure ventilator
Calculation of the incidence rate 
Cases with more specific disease 
diagnosis, including cancer, chronic renal 
failure, liver cirrhoses, neurological 
diseases, stroke and injury: (n=26,784) 
Cases with single disease, n=21,316 
Cases with two or more than two 
specific diseases, n=5,468
Cases with multiple chronic 
disease comorbidities 
analyzed by latent class 
analysis for categorization into 
different clusters (n=23,697) 
Estimation of life expectancies for different categories 
Figure 1 Flow chart of the selection process used for the study cohort.
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Page 3 of 9estimations of life expectancies. During this process, we
grouped several closely related diagnoses together and
converted their original International Classification of
Diseases (Ninth Revision) codes into Clinical Classifica-
tions Software codes [13] so that sufficient numbers
could be obtained for survival analysis. Following the
above direction, the International Classification of Dis-
eases (Ninth Revision) codes for septicaemia included
0031, 0202, 0223, 0362, all subcategories of 038, and
7907 (bacteraemia); those for shock included all subcate-
gories under code 785.
Statistical analysis
Binary and categorical variables were summarised using
frequency counts and percentages. Continuous variables
that were distributed normally are presented as means.
Latent class analysis
To determine the underlying causes that were more
likely to lead to PMV, we applied LCA to group sepa-
rate co-morbidity diagnoses into no more than 10 clus-
ters of in-patients who had undergone PMV. Because
pneumonia and respiratory failure are the most common
reasons for mechanical ventilation, these conditions
were not included in this model. The analysis resulted
in an LCA model consisting of 32 broad diagnosis cate-
gories, which included chronic diseases that had been
previously classified into 260 categories by Clinical Clas-
sifications Software.
LCA assumes that responses are conditionally inde-
pendent within classes after accounting for class mem-
bership [14]. In other words, LCA allows for the
grouping of the PMV patients into several relatively
homogeneous clusters of diagnosis patterns. In con-
structing the model, each cluster or class was named
after the major disease (that is, with the highest preva-
lence or likelihood) present within each age strata.
Akaike Information Criteria were used to assess the
goodness of fit of the model [15]. Lower Akaike Infor-
mation Criteria statistics were considered to indicate a
better statistical fit of the model to the data. If any sin-
gle category exhibited a prevalence approaching 100%
for a given condition across different age groups, then
we assumed that these conditions could be reclassified
into groups with specific diseases, and life expectancy
estimations were conducted separately. Throughout this
process, we found that only stroke could be further
separated from the groups of multiple co-morbidities,
and thus the life expectancy estimation for stroke
patients was performed independently. SAS statistical
software (version 9.1; SAS Institute, Cary, NC, USA)
and R statistical software (version 2.10.1; R Foundation
for Statistical Computing, Vienna, Austria) were used
for the data analyses.
Estimation of life expectancy
Each new patient who fulfilled the definition of PMV
was followed beginning on the first day of PMV treat-
ment and continuing until he/she was deceased or cen-
sored on 31 December 2007. The median survival, or
t h et i m ea tw h i c ho n l yo n e - h a l fo ft h ep a t i e n t sw i t h i na
given category were still alive, was estimated by the
Kaplan-Meier method. In general, most patients did not
survive longer than 1 to 3 years, although some patients
did exhibit a longer survival time. All patients survived
the initial 21 days of treatment by mechanical ventila-
tion, and the survival times reported here exclusively
refer to survival duration thereafter. The lifetime survi-
val of PMV patients (up to 300 months when excluding
those older than 85 years) was thus obtained using a lin-
ear extrapolation of a logit-transformed curve of the
survival ratio between the PMV and an age-matched
and gender-matched reference population generated by
the Monte Carlo method from the life table of the gen-
eral population of Taiwan. The detailed method and
mathematical proof assuming a constant excess hazard
have been described in our previous reports [16-20]. To
facilitate the computation we used ISQoL, a software
program that was built based on the R statistical pack-
age for lifetime expectancy estimation and 300-month
extrapolation (excluding those older than 85 years) and
can be downloaded for free [21].
Validation of the extrapolation method for survival
functions
Empirical PMV data from the National Health Research
Institutes provided us with an opportunity to validate
the actual performance of our semiparametric method
of estimation. We therefore selected subcohorts of
patients beginning on the first day that they received
PMV between 1998 and 2001. We assumed that these
cohorts were only followed until the end of 2001 and
then extrapolated these results to the end of 2007. We
compared our predictions with the Kaplan-Meier esti-
mates of the direct follow-ups from 1998 to 2007.
Assuming that the Kaplan-Meier estimates are the gold
standard, we calculated the relative biases for subcohorts
stratified by different underlying diseases and co-mor-
bidities [22]. The relative biases were computed to com-
pare the differences in values between the Kaplan-Meier
estimates and the Monte Carlo extrapolation method.
Results
Basic characteristics of the prolonged mechanical
ventilation cohort
A total of 50,481 new patients with PMV were included
during the study period (40% female, mean age 72 ±
14.5 years, median survival 0.37 years, and overall life
expectancy 2.68 years). If we counted only the primary
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patient, the top five primary diagnoses were acute
respiratory failure (15%), pneumonia (12%), intracerebral
haemorrhage (5%), septicaemia (3%), and chronic air-
ways obstruction (2%). The tracheotomy rate was 60.1%,
which reflects the ethnic Chinese cultural tradition that
typically avoids additional traumatic wounds if a patient
is expected to pass away soon.
Trends of age-specific incidence rates and cumulative
incidence rates over time
After the NHI began to reimburse long-term usage of
mechanical ventilation to relieve the congested intensive
care ward in 1998, the incidence rate started to rise and
showed an increased trend with older age (Table 1). In
the groups aged 65 to 74 years, 75 to 84 years, and
older than 85 years, increased incidence rates of 76%,
88%, and 119%, respectively, were observed from 1998
to 2004, followed by a slight drop after 2005. The CIR
( 1 7t o8 5y e a r s )i n c r e a s e df r o m0 . 1 0 3i n1 9 9 8t o0 . 1 8 3
in 2004 and then decreased to 0.145 in 2007.
Life expectancies of prolonged mechanical ventilation
patients with specific underlying diseases
The median survival and life expectancies of PMV patients
with different diseases are summarised in Table 2.
Although median survival for most categories was <1 year,
many patients showed life expectancies longer than 2 to
3 years, indicating that some patients survived relatively
long periods of time. The median survival and life expec-
tancies of PMV patients with degenerative neurological
disease, stroke, or injuries were generally longer than those
with chronic renal failure or cancer. When a patient con-
tracted both cancer and chronic renal failure, the median
survival durations and life expectancies were the shortest.
Patients with stroke were initially included in the LCA
because of the presence of multiple co-morbidities, but a
distinctive category of 100% prevalence of stroke consis-
tently appeared across different age strata. We therefore
separated this group and estimated the associated life
expectancies for different age strata, as summarised in
Table 2.
Life expectancies of age-specific clusters in prolonged
mechanical ventilation patients with multiple co-
morbidities
Among the 23,697 PMV patients with multiple co-mor-
bidities, the latent class model usually yielded three or
four clusters, including heart diseases, septicaemia/shock,
chronic obstructive pulmonary diseases, and/or others (for
example, urinary tract infections), as summarised in
Table 3. Diabetes mellitus seemed to be the most frequent
co-morbid disease among all clusters because the preva-
lence rates were all above 14.5%. The life expectancy and
median survival of PMV patients with chronic obstructive
pulmonary disease (COPD) were generally longer than
those of other clustered groups, especially those with sep-
ticaemia/shock. This trend continued until the age of 85,
after which PMV patients with different underlying co-
morbidities seem to show similar outcomes.
Validation results of the extrapolation method
The results obtained to validate our semiparametric
method show that the relative biases were all below
20%. Among them, the relative biases of most PMV
patients with a specific diagnosis ranged between 0.9
and 5.5%. Stroke patients were an exception and usually
suffered from other co-morbidities. Patients with a com-
bination of different diseases (or clusters) appeared less
likely to fulfil the assumption of a constant excess
hazard completely and resulted in greater relative biases,
perhaps because they represent a relatively heteroge-
neous patient population. Nonetheless, the absolute dif-
ferences between our estimates and those obtained
using the Kaplan-Meier method were all below 0.25 life-
years, except for the 65-year-old to 74-year-old multiple
co-morbidity categories, which showed an absolute dif-
ference of 0.39 life-years.
Table 1 Age-specific incidence rates (per 100,000 person-years), and CIR of patients under prolonged mechanical
ventilation
Age group (years) 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Number of new cases 9,296 12,651 12,913 15,660 17,731 19,737 21,818 21,692 20,414 19,723
17 to 34 5.1 6.1 5.5 5.8 6.1 8.4 9.9 9.2 9.4 9.9
35 to 44 10.1 10.8 11.8 14.5 14.4 15.4 19.2 17.4 19.8 18.1
45 to 54 21.8 33.3 29.3 32.4 37.2 42.0 40.5 43.5 39.5 39.7
55 to 64 78.2 101.1 92.2 102.5 111.6 118.9 129.6 119.8 101.7 93.0
65 to 74 224.0 296.5 284.5 329.2 361.9 379.8 393.9 369.2 331.8 306.4
75 to 84 622.0 817.2 814.6 967.2 1,045.5 1,072.3 1,166.4 1,036.0 1,004.6 909.2
≥85 1,182.0 1,536.0 1,702.6 2,064.1 2,253.0 2,563.9 2,584.0 2,554.0 2,161.0 2,046.0
CIR 0.103 0.133 0.132 0.153 0.165 0.173 0.183 0.170 0.159 0.145
CIR, cumulative incidence rate (aged 17 to 85 years).
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Page 5 of 9Table 2 Demographic characteristics and survival of patients undergoing prolonged mechanical ventilation stratified
by different underlying diseases
Number of
cases
Mean age
(SD)
Female
(%)
Median survival
(years)
Life expectancy (SE)
(years)
Cases with single specific disease 21,316 69 (15) 38 0.35 3.40 (0.09)
Cancer 5,367 70 (14) 33 0.17 1.51 (0.13)
Chronic renal failure 2,032 73 (12) 51 0.78 1.36 (0.16)
Liver cirrhosis 1,478 65 (17) 35 0.19 3.59 (0.33)
Multiple sclerosis or degenerative nervous system
conditions
378 65 (17) 39 0.89 4.05 (0.64)
Parkinson’s disease 341 79 (7) 36 0.85 2.06 (0.30)
Stroke 6,765 70 (13) 42 0.72 3.38 (0.15)
Aged <64 years 1,955 53 (9) 35 1.65 5.21 (0.39)
Aged 65 to 74 years 1,818 70 (3) 43 0.77 2.98 (0.17)
Aged 75 to 84 years 2,176 79 (3) 44 0.56 2.09 (0.13)
Aged >85 years 816 88 (3) 54 0.39 1.68 (0.13)
Intracranial and/or spinal cord injury or poisoning 4,955 65 (19) 34 1.06 6.27 (0.24)
Aged <64 years 1,949 45 (14) 26 6.20 10.20 (0.49)
Aged 65 to 74 years 1,116 70 (3) 39 0.82 3.77 (0.22)
Aged 75 to 84 years 13,66 79 (3) 35 0.47 2.67 (0.19)
Aged >85 years 524 88 (3) 48 0.33 1.82 (0.13)
Cases with more than two specific diseases 4,772 68 (15) 39 0.32 2.96 (0.13)
Cancer and chronic renal failure 165 71 (11) 44 0.14 1.21 (0.45)
Cancer and others 1,609 70 (14) 35 0.19 1.88 (0.22)
Chronic renal failure and others 743 70 (13) 50 0.21 1.71 (0.28)
SD, standard deviation; SE, standard error of the mean.
Table 3 Clusters of different co-morbidities categorised by latent class analysis in patients with prolonged mechanical
ventilation
Age <64 years (n = 3,520) Age 65 to 74 years
(n = 5,397)
Age 75 to 84 years
(n = 9,747)
Age >85 years
(n = 5,033)
Class 1 Class
2
Class
3
Class
4
Class
1
Class
2
Class
3
Class
1
Class
2
Class
3
Class
4
Class
1
Class
2
Class
3
Heart
disease
SP/
shock
UTI/
SP
COPD/
other
Heart
disease
SP/
shock
COPD/
other
Heart
disease
SP/
shock
COPD/
other
Respiratory
disease
Heart
disease
SP/
shock
COPD/
other
Number of cases 616 919 197 1,788 1,074 1,824 2,499 1,404 2,856 4,142 1,345 870 1,359 2,804
Prevalence of co-
morbidity (%)
Septicaemia 11.3 62.9 72.2 6.7 10.6 66.1 5.5 11.8 72.8 11.0 7.2 10.2 79.1 11.7
Diabetes mellitus 35.5 26.8 26.1 19.7 39.7 26.1 26.5 27.1 20.5 22.6 17.2 18.6 14.5 14.6
Hypertension 17.9 4.9 9.8 8.3 20.8 6.8 13.9 16.1 4.8 17.3 12.5 15.4 3.3 15.2
AMI/coronary
atherosclerosis
39.9 3.9 2.3 2.4 43.9 4.6 5.2 42.8 5.5 6.6 4.0 42.8 5.6 4.0
COPD 6.5 3.2 0.5 17.9 11.0 11.0 33.9 18.2 12.4 39.6 29.6 24.9 12.7 33.0
Other respiratory
disease
21.8 23.7 13.8 30.1 22.3 18.1 26.7 20.9 17.2 0 100 24.6 19.4 25.9
Acute renal failure 12.2 20.6 9.5 4.8 12.7 16.4 4.5 12.1 16.7 4.2 5.3 8.7 15.2 5.6
UTI 5.3 0 100 14.8 5.7 25.1 21.1 11.7 28.0 24.3 21.1 16.1 30.6 29.0
Shock 11.2 39.6 33.1 2.7 10.3 39.1 2.7 8.9 38.5 4.9 3.7 7.3 41.6 5.0
Heart failure 42.2 3.2 2.6 2.4 37.0 5.8 4.8 50.1 7.2 7.7 7.4 50.5 8.3 7.7
Median survival
(years)
0.80 0.34 0.88 1.64 0.39 0.23 0.55 0.29 0.21 0.95 0.38 0.32 0.20 0.35
Life expectancy
(years) (SE)
5.09
(0.60)
4.51
(0.49)
4.82
(1.49)
5.25
(0.37)
2.55
(0.21)
2.14
(0.13)
2.56
(0.13)
1.86
(0.23)
1.66
(0.10)
2.12
(0.07)
2.18 (0.17) 1.48
(0.12)
1.12
(0.07)
1.52
(0.05)
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; SE, standard error of the mean; SP, septicaemia; UTI, urinary tract infections.
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To our knowledge, this is the first study to analyse a
nationally representative PMV dataset to estimate the
incidence rates, CIR, and life expectancies stratified by
age and different clusters of diagnoses. Our findings
showed that new cases of PMV increased significantly
from 9,296 to 21,818 between 1998 and 2004. The age-
specific incidence rates increased as people grew older, a
result consistent with previous reports from scholars in
the United States and Canada [1,2,4,23]. The highest
age-specific incidence rate of PMV was observed in
patients older than 85 years in Taiwan, however, and
this rate was approximately four to five times higher
than those reported in the United States [24]. We
attempted to quantify the lifetime risk of PMV by calcu-
lating the CIR17 to 85, which increased from 0.103 to
0.145 between 1998 and 2007 (Table 1). This finding
implies that an adult person in Taiwan who lives until
the age of 85 has a 10 to 15% chance of requiring PMV.
Given the resource-intensiveness of PMV, this issue
requires special attention. When the Bureau of the NHI
of Taiwan began to audit the quality of the integrated
respiratory care system in 2003, including the rates of
successful weaning, readmission, and nosocomial infec-
tion, the incidence of PMV appeared to stabilise and
decreased slightly, as summarised in Table 1.
In the past, there has been a general lack of data
regarding the life expectancies associated with different
diagnoses for patients undergoing PMV. This has made it
difficult for stakeholders to reach consensus clinical deci-
sions regarding optimal treatment strategies. The issue
becomes even more complicated when payment is pro-
vided via NHI or a third party. It is understandable that
the patient and his/her family always expect successful
weaning and good recovery, even after longer than 21
days of continuous mechanical ventilation or PMV.
According to our previous study, however, most patients
undergoing PMV survive only approximately 1.5 to 2
years, and approximately 62% of them suffer from cogni-
tive impairments and poor quality of life. Accounting for
these factors results in an overall quality-adjusted life
expectancy of only 0.3 to 0.4 and 0.6 to 0.7 quality-
adjusted life-years [25,26]. The present study therefore
further provided crucial estimates of the median survival
and life expectancies of patients undergoing PMV with
different diagnoses or co-morbidities, as summarised in
Tables 2 and 3. Table 2 shows that the life expectancies
were shortest for PMV patients with chronic renal failure
and cancer or any condition co-morbid with them, fol-
lowed by Parkinson’s disease and stroke. In contrast, the
life expectancies for degenerative neurological diseases,
liver cirrhosis, injuries, and poisonings were >3.6 years.
When stratified by age categories, the median survival
and life expectancies for PMV patients older than 85
years were <4.6 months and <21.8 months, respectively,
which were also observed for all of the different types of
co-morbidities (Tables 2 and 3). The above figures call
into question the cost-effectiveness of current policies
and should be considered by policy-makers and the pub-
lic in discussions regarding the bioethics of PMV care,
especially given the limited resources of the NHI in
Taiwan. Although more and more countries have tried to
implement the principle of universal coverage in their
national health insurance plans [27], our results provide
data highlighting the needed evidence for developing
strategies of sustainable management.
Although previous studies have shown similar charac-
teristics of multiple co-morbidities in PMV patients,
these reports did not stratify patients into special clus-
ters [1,9,24,28]. The LCA showed that the underlying
co-morbidities associated with PMV could be largely
classified into the major categories of heart diseases,
septicaemia/shock, and COPD based on the high preva-
lence of each cluster. Overall, LCA indicates that the life
expectancies generally decreased with older age. In par-
ticular, we found that approximately 50% of the PMV
patients with a combination diagnosis of septicaemia
and shock usually survived <4 months, and their life
expectancies were usually shorter than those determined
for the other clusters within the same age stratum. The
generally longer survival time of PMV patients with
COPD corroborated the hypothesis that the establish-
ment of mechanical ventilation provides more direct
access for clinicians to solve problems coming from the
respiratory tract, while patients with other underlying
diseases may not be improved significantly unless their
underlying disorders were also resolved. This advantage
disappeared in individuals over 85 years of age because
a high proportion of these COPD patients also suffered
from other major diseases, including urinary tract infec-
tion (29%) and other respiratory diseases (26%), as
shown in Table 3.
Our study has several limitations. First, the database did
not contain any information regarding the severity and/or
actual clinical data of the PMV patients. We were there-
fore unable to further stratify these patients. Because they
were all under PMV care for longer than 21 days, however,
all of the patients were associated with extremely severe
conditions, which resulted in a very short life expectancy
and suggested that 10 years of follow-up time would be
usually sufficient. Second, because the recorded diagnoses
must fulfil all of the reimbursement regulations of the
N H I ,i ti sp o s s i b l et h a ts o m ed i a g n o s e sa r eo v e r - r e p r e -
sented because they were more easily reimbursed. How-
ever, the NHI of Taiwan has offered a list of 30 major
categories of catastrophic illnesses that are exempt from
partial co-payments, and each has its specific diagnostic
criteria to prevent any abuse [29]. For example, all types of
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Page 7 of 9malignant neoplasm do not require co-payments, and evi-
dence of histopathology and/or cytology is generally
required for diagnoses of cancer. A diagnosis of end-stage
renal disease requires documentation of chronic kidney
disease with an irreversible creatinine level >8 mg/dl, or
creatinine level >6 mg/dl with diabetes mellitus as a co-
morbid condition [30]. There are therefore strict criteria
for almost all of the major diagnoses listed in Table 2. The
potential selection bias for the common diseases listed in
Table 3 is probably minimal because the 43 broad cate-
gories were collapsed from the 260 categories of Clinical
Classifications Software codes [13], and LCA ensured that
each category was as homogeneous as possible.
Conclusions
The number of PMV patients in Taiwan has increased
during the past decade. Patients with different underly-
ing diseases showed different median survival and life
expectancies. The establishment of mechanical ventila-
tion directly targets problems of the respiratory tract
and provides sustainable ventilation, which may improve
the survival of patients with COPD or degenerative neu-
rological diseases more than those with other underlying
causes such as septicaemia/shock, heart failure, cancer,
or end-stage renal disease. The advantages of PMV
seem to decrease for the older patient, however, espe-
cially those aged over 85. The results also call for
further evaluation of the cost-effectiveness and bioethics
of such care in Taiwan, and highlight the need for early
planning of resource allocation in any system of health
insurance with universal coverage.
Key messages
￿ The number of new patients undergoing treatment
with PMV has increased rapidly during the past dec-
ade in Taiwan.
￿ The life expectancies of PMV patients with degen-
erative neurological diseases, stroke, or injuries/poi-
soning as their primary co-morbidity seemed to
survive longer than those with chronic renal failure
or cancer, or a co-morbidity with them.
￿ Among PMV patients with multiple co-morbidities,
those with COPD as the major underlying co-
morbidity seem to survive longer than patients with
other co-morbidities, perhaps because this treatment
specifically targets the respiratory tract, which is com-
promised in COPD. The benefits of PMV decrease for
the older patient, especially those aged over 85.
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